Real-World HbA1c Changes Among Type 2 Diabetes Mellitus Patients Initiating Treatment With a 1.0 Mg Weekly Dose of Semaglutide for Diabetes

Real-World HbA1c Changes Among Type 2 Diabetes Mellitus Patients Initiating Treatment With a 1.0 Mg Weekly Dose of Semaglutide for Diabetes

# Background Medical management of patients with type 2 diabetes mellitus (T2DM) is complex because of the chronic nature of the disease and its associated comorbidities. Injectable once-weekly semaglutide for diabetes (OW sema T2D) is a type of glucagon-like peptide–1 receptor agonist approved for...

Full description

Saved in:
Bibliographic Details
Main Authors: Noelle N. Gronroos, Caroline Swift, Monica S. Frazer, Andrew Sargent, Michael Leszko, Erin Buysman, Sara Alvarez, Tyler J. Dunn, Josh Noone
Format: Article
Language:English
Published: Columbia Data Analytics, LLC 2024-11-01
Series:Journal of Health Economics and Outcomes Research
Online Access:https://doi.org/10.36469/001c.124111
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items